Download Ebook: Top 20 Big Data projects in Pharma & Biotech – Part 1

The promise of big data Every patient experience generates a massive amount of data which, when pooled together, can give a detailed account of their health, the effectiveness & safety of the drugs they are taking and when aggregated from other patient's data a vast library of information about entire disease states and clinical populations. Understandably pharma is now armouring …

The Top 10 Biotech Earners

The top 10 public biotechnology companies in terms of revenue generation posted combined sales of $93.01 billion last year (2012), a growth of 12.1% on 2011. The list below shows that one biotechnology company posted sales accounting for a third of that revenue (Source: PharmaLive): Rank (2012) Company Revenue in 2012 Net Income in 2012 1 Roche $34,935,779,034(biotech sales estimate) …

The Top 10 Biotech R&D Spenders

The top 10 public biotechnology companies in terms of R&D expense forked out $23.81 billion last year (2012), a growth of 14.7% on 2011. As you can see, one biotech company accounted for well over a third of that expenditure (Source: PharmaLive). Rank (2012) Company R&D Expense (2012) 1 Roche (entire Roche Group) $10,186,626,853 2 Amgen Inc. $3,380,000,000 3 Novo …

Guest blog: The Biotech Bull and its impact on the future of Regenerative Medicine

‘Alternative financing models' by Dr. Navid Malik As head of life sciences research at Cenkos securities and with a background in science, Dr. Malik’s words carried bullish weight as he assured there's a 10 year bull market in Biotech just around the corner.  Whilst being what any stem cell researcher and regenerative medicine financer wants to hear the reference was …

The impact of comparability on orphan drug development

As we've been hearing from pharma and biotech executives in the rare disease space in recent years, market access is a key element in supporting the expansion and development of orphan drugs around the globe. This issue is really dynamic as it is impacted by challenges from the very early drug discovery stage, to clinical trials, manufacturing and consequently the …

The reasons why the whole industry is repurposing drugs

Finding new therapeutic uses for old drugs is a growing trend in the industry. as pharma struggles to discover new blockbuster drugs and see in the practice a way to rebuild their pipelines. Although drug repositioning may sound a strategy only applicable for big pharmaceutical, but small spin-out biotechs are taking advantage of the declining cost of screening of small …

Infographic: Top 10 regions in biotechnology applications

  Based on patent and investment data, Assay Depot has designed a detailed infographic showing the most innovative regions in the world in regards to biotechnology applications. This infographic is a great indicator of future hotspots for drug discovery breakthroughs. Were there any surprises? Are there any regions that didn't make the list? See the full infographic here     …

Download: How to overcome market access challenges and find new business models

            Everyone seems to be talking about market access these days, but do we actually know what it entails and what the current issues are surrounding it?  We caught up with Dr Andy Stainthorpe, Associate Director, National Institute for Health and Clinical Excellence (UK) to get his insight on the following: Market access issues that …

Top 3 ways Big Pharma is harnessing technology

In the coming year, the main drive for the big pharma industry will be cost-cutting and efficiency.  Through the use of new forms of technology that have presented themselves in the market, pharmaceutical companies are looking to harness new technology to become more efficient and maximise investment opportunities. The top ways Big Pharma is harnessing technology: Data Mining: Data mining …